Capricor Therapeutics (CAPR) Receivables (2023 - 2025)

Capricor Therapeutics' Receivables history runs 14 years deep, the most recent figure standing at $59167.0 for Q4 2025.

• In Q4 2025, Receivables fell 99.71% year-over-year to $59167.0; the TTM figure through Dec 2025 stood at $59167.0 (down 99.71% YoY), while the FY2025 annual figure was $59167.0, down 99.71% from the prior year.
• Receivables for Q4 2025 stood at $59167.0, roughly flat from $59167.0 in the prior quarter.
• The five-year high for Receivables was $20.4 million in Q4 2023, with the low at $59167.0 in Q3 2025.
• The 5-year median for Receivables is $400716.0 (2021), against an average of $2.6 million.
• The sharpest annual moves came in 2023 and 2025: Receivables surged 3620.37% in 2023, then sank 99.71% in 2025.
• Capricor Therapeutics' Receivables stood at $391750.0 in 2021, then surged by 39.78% to $547580.0 in 2022, then soared by 3620.37% to $20.4 million in 2023, then decreased by 0.02% to $20.4 million in 2024, then tumbled by 99.71% to $59167.0 in 2025.
• Business Quant data shows CAPR's Receivables at $59167.0 in Q4 2025, $59167.0 in Q3 2025, and $59509.0 in Q2 2025.